PDF(1120 KB)
Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma
FENG Li-Juan, ZHANG Guo-Ping, XIE Min, CAO Peng-Fei, FU Chun-Yan, HU Zhong-Liang, DAI Mao
Chinese Journal of Contemporary Pediatrics ›› 2009, Vol. 11 ›› Issue (07) : 555-558.
PDF(1120 KB)
PDF(1120 KB)
Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma
OBJECTIVE: Some research has shown that primary intestinal lymphoma with the same immunophenotype has different prognosis. It suggests that the prognosis of this disease is not determined by a single factor but may be related to genetic or chromosomal variations. The p53 gene is an important tumor suppressor gene, and 13q14 deletion is a common chromosomal abnormality of lymphocyte proliferation diseases. This study aimed to explore the role of the p53 gene and chromosome 13q14 variations in the assessment of prognosis in primary intestinal lymphoma. METHODS: p53 gene and chromosome 13q14 expression in paraffin sections of 30 cases of primary intestinal lymphoma and 10 cases of lymph node reactive hyperplasia were ascertained using an improved FISH technique. RESULTS: p53 gene deletion was found in 22.7% of patients with primary intestinal lymphoma at stage I-II and in 75.0% of patients at stage III-IV (χ2=6.903, P<0.01). The 30 patients with primary intestinal lymphoma were pathologically classified into-mucosa-associated lymphoid tissue (MALT) (n=14) and non-MALT types (n=16). The MALT lymphoma group had significantly lower incidence of p53 gene deletion (14.3% vs 56.3%; χ2=5.662, P<0.05). Average survival time in patients with p53 gene deletion was 13.41 months, being shorter than the patients with normal p53 gene (36.1 months) (t=2.637, P<0.05). 13q14 deletion was found in 40.0% of patients with primary intestinal lymphoma, but none of patients with lymph node reactive hyperplasia showed 13q14 deletion. 13q14 deletion was not significantly related to the pathological type and the clinical stage of primary intestinal lymphoma as well as the survival time. There was no significant correlation between p53 gene and 13q14 deletions. CONCLUSIONS: There was a high incidence of p53 gene deletion in patients with non-MALT lymphoma or at stage III-IV. p53 gene deletion is related to a high tumor malignant degree and a poor prognosis, while-chromosome 13q14 variation is not associated with the prognosis in patients with primary intestinal lymphoma.［Chin J Contemp Pediatr, 2009, 11 (7):555-558］
Primary intestinal lymphoma / Gene expression / FISH / p53 / 13q14 / Prognosis
［1］Hammer GP, Seidenbusch MC, Schneider K, Regulla DF, Zeeb H, Spix C,et al. A cohort study of childhood cancer incidence after postnatal diagnostic X-ray exposure［J］. Radiat Res, 2009, 171(4):504-512.
［2］Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extra nodal non-Hodgkin′s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry［J］. Ann Oncol, 2003, 14(1):131-139.
［3］尹丽霞,张伟京.B细胞非霍奇金淋巴瘤重要相关基因的研究进展［J］.国外医学药学分册, 2006, 33(3):174-177.
［4］张恒,罗春英,许 洁，邓飞. p53基因突变与非霍奇金淋巴瘤病因学关系研究［J］.现代医药卫生，2008, 24（9）:1268-1269.
［5］Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract.Report of 37 cases with a study of factors influencing prognosis［J］. Br J Surg, 1961, 49(7):80-89.
［6］赵宝玉,边大鹏,汪欣,汤坚强,万远廉,刘玉村.原发性胃肠道淋巴瘤的诊断与治疗［J］.中国肿瘤临床与康复, 2007, 14(5):446-449.
［7］Musshoff K. Clinical staging classification of non-Hodgkin′s lymphomas［J］. Strahlentherapie, 1977, 153(4):218-221.
［8］景红梅,克晓燕,董菲.49例MALT淋巴瘤临床资料分析［J］.中国实验血液学杂志, 2007, 15（6）：1293-1296.
［9］Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A. High incidence of t(11; 18)(q21; q21)in Helicobacter pylori-negative gastric MALT lymphoma［J］. Blood, 2003, 101(7):2547-2550.
［10］Theodoropoulos GE, Karafoka E, Papailiou JG, Stamopoulos P, Zambirinis CP, Bramis K, et al. P53 and EGFR expression in colorectal cancer: a reappraisal of ′old′ tissue markers in patients with long follow-up［J］.Anticancer Res, 2009, 29(2):785-791.
［11］罗春英,邓飞,刘曙光.T细胞淋巴瘤p53突变与其周围微卫星改变的研究［J］.第三军医大学学报, 2008, 30(5)：399-401.
［12］罗春英,邓飞.非霍奇金淋巴瘤中p53 基因突变情况研究［J］.右江民族医学院学报,2006,5（5）：712-714.
［13］黄波，郭瑞珍.儿童非霍奇金淋巴瘤与p53蛋白表达的关系［J］.贵州医药,2003,27(5): 409-411.
［14］韩蕴丽,刘壮,韦红英,李树全. p16和p53蛋白在儿童非霍奇金淋巴瘤的表达［J］.广西医学, 2008, 30(7):957-959.
［15］Xu W, Li JY, Pan JL, Qiu HR, Shen YF, Li L. Interphase fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia［J］. Int J Hematol, 2007, 85(5):430-436.
［16］Brito-Babapulle V, Baou M, Matutes E, Morilla R, Atkinson S, Catovsky D. Deletions of D13S25, D13S319 and RB-1 mapping to 13q14.3 in T-cell prolymphocytic leukaemia［J］. Br J Haematol, 2001, 114(2):327-332.
